ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS.   Almost all cases of ALS, and about half of cases of […]

Continue Reading

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Larry Altstiel M.D. Ph.D., as Chief Medical Officer.   Brings decades of experience in Alzheimer’s research […]

Continue Reading

NemaLife and UC Davis enter into a research partnership to test the therapeutic potential of several novel psychoplastogens developed in David E. Olson’s Lab

NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.   NemaLife will evaluate the efficacy of these compounds using its high-throughput C. elegans-based in vivo screening platform. This high-throughput […]

Continue Reading

ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders

ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce it has mailed the Notice of Notice-and-Access (the “N&A Notice”) to shareholders of record of the Corporation as of April 01, 2022, in connection with the Annual General and Special Meeting of the Shareholders (the “Meeting”) of the Corporation to be […]

Continue Reading

ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has presented at the  American Academy of  Neurology (AAN) Annual Meeting held at the Washington State Convention Center in […]

Continue Reading

ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March […]

Continue Reading

How Significant Is Innovation in Nursing

The purpose of innovation in nursing is to improve the quality of care delivered and to reduce the associated risks.   The definition of innovation must be broad enough to include not only innovations that are brought about by changes in technology, but also change made through social, cultural, or behavioral factors. Innovation may also […]

Continue Reading
Close-up of man using nasal spray

Azelastine – the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of SARS-CoV-2

CEBINA GmbH, Central European Biotech Incubator and Accelerator with its partner URSAPHARM Arzneimittel GmbH, today announce new results demonstrating that azelastine, the active drug in Pollival®, URSAPHARM’s widely available anti-allergy nasal spray, is an effective anti-viral against the globally dominant omicron SARS-CoV-2 variant in laboratory conditions.   Previously, CEBINA and URSAPHARM have demonstrated that azelastine […]

Continue Reading